In the other report, Celgene Inc. 's Revlimid doubled the number of myeloma patients whose disease remained in remission three years after treatment began, compared with those on placebo.
在另外一篇报告里，Celgene公司的Revlimid药在开始服用后的三年内脊髓瘤患者处于缓解期的人数比服用安慰剂组的数量增加了一倍。
In the other report, Celgene Inc. 's Revlimid doubled the number of myeloma patients whose disease remained in remission three years after treatment began, compared with those on placebo.
在另外一篇报告里，Celgene公司的Revlimid药在开始服用后的三年内脊髓瘤患者处于缓解期的人数比服用安慰剂组的数量增加了一倍。
应用推荐